Dr.Reddys Lab (BSE: 500124) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,15,464 Cr, it ranks #101 by market cap among the 6,197 Indian listed companies on FinBizNet, and #4 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,380.00 (as of 16 Nov 2026), the share price is 2.5% below its 52-week high of ₹1,414.90 and 25.3% above its 52-week low of ₹1,101.00. The share price is up 14.5% over one year and up 14.4% over three months.
| Current Price | ₹1,380.00 |
|---|---|
| Market Cap | ₹1,15,464 Cr |
| BSE Code | 500124 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 26.9 |
| Return on Equity | 11.52% |
| Return on Assets | 5.74% |
| 52-Week Range | ₹1,101.00 – ₹1,414.90 |
| 1-Year Price Change | +14.5% |
| 3-Month Price Change | +14.4% |
| Beta (1Y) | -0.11 |
| Dividend Yield | 0.58% |
| Headquarters | Hyderabad, Telangana |
| Website | www.drreddys.com |
| Revenue | ₹8,698 Cr |
|---|---|
| Net Profit | ₹913 Cr |
| Net Margin | 10.5% |
| EPS (Basic) | ₹11.10 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Dr.Reddys Lab reported revenue of ₹8,698 Cr in Q2 FY27, down 1.5% from ₹8,828 Cr in Q2 FY26 and up 7.4% from ₹8,100 Cr in Q1 FY27. It posted a net profit of ₹913 Cr for the quarter, against a net profit of ₹1,337 Cr in Q2 FY26 (down 31.7%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹7,546 Cr (Q4 FY26) to ₹8,828 Cr (Q2 FY26). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹8,698 Cr | ₹913 Cr | 10.5% |
| Q1 FY27 | ₹8,100 Cr | ₹436 Cr | 5.4% |
| Q4 FY26 | ₹7,546 Cr | ₹221 Cr | 2.9% |
| Q3 FY26 | ₹8,753 Cr | ₹1,190 Cr | 13.6% |
| Q2 FY26 | ₹8,828 Cr | ₹1,337 Cr | 15.1% |
| Q1 FY26 | ₹8,572 Cr | ₹1,410 Cr | 16.4% |
| Q4 FY25 | ₹8,528 Cr | ₹1,587 Cr | 18.6% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 26.63% of Dr.Reddys Lab's shares as of Sept 2026, against 26.64% in Sept 2025 (−0.01 percentage points). Delivery averaged 53.8% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and
1. Global Generics-This segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. It also engages in biologics business. 2. Pharmaceutical Services and Active Ingredients (PSAI)-This segment manufactures and markets active pharmaceutical ingredients and intermediates, which are the principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. 3. Others-This segment engages in the biotechnology business. It develops therapies in the fields of oncology and inf
1. Global Generics-89% 2. Others-0.6% 3. Pharmaceutical Services and Active Ingredients (PSAI)-12.5%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Glenmark Pharmaceuticals Limited | ₹75,556 Cr | 55.1 | 14.07% | ₹4,157 Cr | +45.7% |
Listed by market capitalisation. Ratios are shown for context only.
Dr.Reddys Lab is trading at ₹1,380.00, with a market capitalisation of ₹1,15,464 Cr.
Dr.Reddys Lab operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Dr.Reddys Lab has a P/E of 26.9 and a return on equity of 11.52%.
Dr.Reddys Lab is listed on the BSE under the scrip code 500124.
Dr.Reddys Lab's share price is up 14.5% over one year and up 14.4% over three months. Its 52-week range is ₹1,101.00 to ₹1,414.90.
In Q2 FY27, Dr.Reddys Lab reported revenue of ₹8,698 Cr and net profit of ₹913 Cr, with basic EPS of ₹11.1 (consolidated, parsed from the company's exchange filing).
Dr.Reddys Lab reported revenue of ₹8,698 Cr in Q2 FY27, down 1.5% from ₹8,828 Cr in Q2 FY26 and up 7.4% from ₹8,100 Cr in Q1 FY27.
Promoters held 26.63% of Dr.Reddys Lab's shares as of Sept 2026, against 26.64% in Sept 2025 (−0.01 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.